Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10027189 | 0.86 | LMNA (0.34) | MAPTLMNATP53DHFRAURKA | |
| SCHEMBL19361118 | 0.86 | AURKA (0.36) | MAPTLMNATP53DHFRAURKA | |
| SCHEMBL10027311 | 0.85 | MAPT (0.36) | MAPTLMNATP53DHFRAURKA | |
| SCHEMBL24345070 | 0.81 | MAPT (0.36) | MAPTLMNATP53DHFR | |
| SCHEMBL17808748 | 0.81 | LMNA (0.32) | MAPTLMNATP53DHFR | |
| SCHEMBL21577493 | 0.81 | ALDH1A1 (0.35) | MAPTLMNAHSD17B10 | |
| SCHEMBL17802274 | 0.81 | CHEK1 (0.51) | MAPTLMNATP53DHFRAURKA | |
| SCHEMBL17802279 | 0.80 | MAPT (0.34) | MAPTLMNATP53DHFR | |
| SCHEMBL17808794 | 0.80 | JAK2 (0.39) | MAPTLMNATP53AURKAPRKCI | |
| SCHEMBL17808764 | 0.80 | PDE3B (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227292-B1 | 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS | ALTERITY THERAPEUTICS LTD (AU) | 2022-03-09 | — | — | EP | disclosed |
| US-20210230159-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2021-07-29 | — | — | US | disclosed |
| US-11008319-B2 | 4H-pyrido[1,2-a]pyrimidin-4-one compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2021-05-18 | — | — | US | disclosed |
| US-20200317670-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2020-10-08 | — | — | US | disclosed |
| US-10738050-B2 | 4H-pyrido[1,2-A]pyrimidin-4-one compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2020-08-11 | — | — | US | disclosed |
| US-20190352301-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2019-11-21 | — | — | US | disclosed |
| US-10287285-B2 | 4H-pyrido[1,2-A]pyrimidin-4-one compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2019-05-14 | — | — | US | disclosed |
| US-20170267676-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2017-09-21 | — | — | US | disclosed |
| US-20170267676-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2017-09-21 | — | — | US | disclosed |
| WO-2016086261-A1 | 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2016-06-09 | — | — | WO | disclosed |
| EP-2044026-B1 | METHOD OF TREATMENT OF GLIOMA BRAIN TUMOUR | PRANA BIOTECHNOLOGY LTD (AU) | 2014-03-26 | — | — | EP | disclosed |
| US-8163760-B2 | Use of pyridopyrimidine compounds in the treatment of gliomas | PRANA BIOTECHNOLOGY LIMITED (AU) | 2012-04-24 | — | — | US | disclosed |
| US-8163760-B2 | Use of pyridopyrimidine compounds in the treatment of gliomas | PRANA BIOTECHNOLOGY LIMITED (AU) | 2012-04-24 | — | — | US | disclosed |
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-03-18 | — | — | US | disclosed |
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-03-18 | — | — | US | disclosed |
| WO-2007147217-A1 | METHOD OF TREATMENT OF GLIOMA BRAIN TUMOUR | PRANA BIOTECHNOLOGY LIMITED (AU) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738050-B2 | 4H-pyrido[1,2-A]pyrimidin-4-one compounds | PSEN2, PSEN1, PNPO | MAPT 38/4885LMNA 1246/4885TP53 3017/4885 |
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | MGMT, DHFR, IDH2 | MAPT 1067/4885LMNA 2250/4885TP53 10/4885 |
| US-20200317670-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PSEN2, PSEN1, PNPO | MAPT 38/4885LMNA 1246/4885TP53 3017/4885 |
| US-10287285-B2 | 4H-pyrido[1,2-A]pyrimidin-4-one compounds | PSEN2, PSEN1, PNPO | MAPT 38/4885LMNA 1246/4885TP53 3017/4885 |
| US-11008319-B2 | 4H-pyrido[1,2-a]pyrimidin-4-one compounds | PSEN2, PSEN1, PNPO | MAPT 38/4885LMNA 1246/4885TP53 3017/4885 |
| US-20190352301-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PSEN2, PSEN1, PNPO | MAPT 38/4885LMNA 1246/4885TP53 3017/4885 |
| US-20210230159-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PSEN2, PSEN1, PNPO | MAPT 38/4885LMNA 1246/4885TP53 3017/4885 |
| US-20170267676-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS | PSEN2, PSEN1, PNPO | MAPT 38/4885LMNA 1246/4885TP53 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.